Hence, uncovering the molecular mechanisms by which ALX/FPR2 is regulated in CF can offer the basis for a better understanding of CF pathophysiology and the designing of innovative therapeutics that activate endogenous resolution circuits. This evidence concerns the gene FPR2 and cystic fibrosis.